DDInter927 DDInter1771
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Teriflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Teriflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melatonin
Teriflunomide {u} may lead to a major life threatening interaction when taken with {v} Mephenytoin
Teriflunomide {u} may lead to a major life threatening interaction when taken with {v} Asparaginase Erwinia chrysanthemi
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Melatonin
Teriflunomide may lead to a major life threatening interaction when taken with Mephenytoin
Teriflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi